You're signed outSign in or to get full access.
Research Analyst at Malaria
No evidence was found of a Marco Seru working as an analyst or holding any finance or research role at a firm called Malaria. There is no LinkedIn profile, analyst ranking, company coverage, metrics, or record of credentials for Marco Seru associated with this industry. Available search results are related to scientific research on malaria and do not include any professional profiles by this name in the finance or investment analysis sector.
Marco Seru asked a technical question regarding the specific amount of the charge registered under 'other expenses' that was related to the sale of non-core properties during the quarter.
CFO Mariano Biglia provided a direct answer, stating that the net loss registered in the 'other expenses' line item from the sale of non-core properties was 5 billion pesos.
Fintool can predict 
SUPV's earnings beat/miss a week before the call
Marco Seru submitted a written question asking for the specific amount of the charge registered under 'other expenses' related to the sale of non-core properties during the quarter.
CFO Mariano Biglia responded directly, stating that the net loss registered in that line item for the sale of non-core properties was 5 billion pesos.
Fintool can write a report on SUPV's next earnings in your company's style and formatting